GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (FRA:0ET) » Definitions » ROE % Adjusted to Book Value

Esperion Therapeutics (FRA:0ET) ROE % Adjusted to Book Value : Negative Equity% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Esperion Therapeutics ROE % Adjusted to Book Value?

Esperion Therapeutics's ROE % for the quarter that ended in Mar. 2024 was Negative Equity. Esperion Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Esperion Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was Negative Equity.


Esperion Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Esperion Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics ROE % Adjusted to Book Value Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.49 - - - -

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - Negative Equity

Competitive Comparison of Esperion Therapeutics's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's ROE % Adjusted to Book Value falls into.



Esperion Therapeutics ROE % Adjusted to Book Value Calculation

Esperion Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Esperion Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (FRA:0ET) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics (FRA:0ET) Headlines

No Headlines